Rank ligand inhibition with OPG-FC enhances the inhibitory effect of docetaxel on the growth of prostate cancer PC-3 tumors in the mouse skeleton

被引：0
|
作者：
Miller, R.
Roudier, M.
Jones, J.
Tometsko, M.
Armstrong, A.
Canon, J.
Dougall, W.
机构：
[1] Amgen Inc, Seattle, WA USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
CALCIFIED TISSUE INTERNATIONAL | 2007年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 50 条
  • [1] Administration of the RANK ligand inhibitor (OPG-Fc) enhances the inhibitory effect of docetaxel on the growth of prostate cancer PC-3 tumors in the mouse skeleton.
    Miller, R.
    Roudier, M.
    Jones, J.
    Tometsko, M.
    Armstrong, A.
    Canon, J.
    Dougall, W.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S84 - S84
  • [2] Antitumor efficacy of the RANK ligand inhibitor OPG-Fc in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models.
    Miller, R
    Jones, J
    Tometsko, M
    Armstrong, A
    Zhang, N
    Leal, J
    Trueblood, E
    Dougall, W
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S117 - S117
  • [3] Direct effects of RANK ligand (RANKL) antagonism by osteoprotegerin (OPG:Fc) on prostate cancer (PC3) cells in vivo
    Armstrong, AP
    Miller, RE
    Tometsko, M
    Jones, J
    Chaisson, ML
    Branstetter, D
    Dougall, WC
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P4 - P4
  • [4] The RANK ligand inhibitor OPG-Fc reduces bone lesions and skeletal tumor burden in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models
    Miller, R.
    Jones, J.
    Tometsko, M.
    Armstrong, A.
    Canon, J.
    Trueblood, E.
    Roudier, M.
    Dougall, W.
    EJC SUPPLEMENTS, 2006, 4 (12): : 108 - 108
  • [5] Enhanced inhibition of PC-3 xenograft prostate tumor growth by combination of green tea and quercetin with docetaxel
    Wang, Piwen
    Henning, Susanne
    Heber, David
    Vadgama, Jaydutt
    CANCER RESEARCH, 2015, 75
  • [6] Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model
    Muramaki, M
    Miyake, H
    Hara, S
    Kamidono, S
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (03) : 623 - 628
  • [7] Synergistic Anti-Tumor Activity of Oncolytic Reovirus and Docetaxel in a PC-3 Prostate Cancer Mouse Model
    Heinemann, Lucy
    Kottke, T.
    Vile, R.
    Coffey, M. C.
    Harrington, K.
    Melcher, A.
    Pandha, Hardev S.
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 951 - 952
  • [8] Preparation of novel (-)-gossypol nanoparticles and the effect on growth inhibition in human prostate cancer PC-3 cells in vitro
    Jin, Cai-Ling
    Chen, Mei-Ling
    Wang, Ying
    Kang, Xiao-Chun
    Han, Guang-Ye
    Xu, Su-Ling
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (03) : 675 - 678
  • [9] Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells
    JIANG HaiXIA DanWU Lingjiao and CHEN Zhaodian Department of Urology Department of Infectious DiseaseFirst Affiliated HospitalZhejiang University School of MedicineHangzhou Zhejiang China
    中华医学杂志（英文版）, 2011, (23) : 4018 - 4021
  • [10] Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells
    Jiang Hai
    Xia Dan
    Wu Ling-jiao
    Chen Zhao-dian
    CHINESE MEDICAL JOURNAL, 2011, 124 (23) : 4018 - 4021
12345